Anti-diabetic therapies and the risk of acute pancreatitis: A nationwide retrospective cohort study from Taiwan

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 6, 2015, Pages 567-575

  Chang, Hsien Yen ^a   Hsieh, Chi Feng ^b   Singh, Sonal ^a,c   Tang, Wenze ^d   Chiang, Yi Ting ^b   Huang, Weng Foung ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Acute pancreatitis; Anti diabetic therapies; Cohort study; Dipeptidyl peptidase 4, metformin; Pharmacoepidemiology; Sulfonylurea

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; ADULT; ARTICLE; COHORT ANALYSIS; DIABETIC PATIENT; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REIMBURSEMENT; RETROSPECTIVE STUDY; SAMPLE SIZE; TAIWAN; ADOLESCENT; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RISK ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PANCREATITIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS; TAIWAN; YOUNG ADULT;

EID: 84930415249     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3770     Document Type: Article

References (42)

1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298(2): 194-206.
2. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53(1): 153-159.
3. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009; 58(7): 1604-1615.
4. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014; 370(9): 794-797.
5. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014; 348: g2366.
6. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012; 98(2): 271-284.
7. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4(1): 119-145.
8. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32(5): 834-838.
9. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141(1): 150-156.
10. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013; 50(4): 569-577.
11. Faillie JL, Babai S, Crepin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French pharmacovigilance database. Acta Diabetol 2014; 51(3): 491-497.
12. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012; 14(10): 904-911.
13. Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug Saf 2014; 37(7): 521-528.
14. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33(11): 2349-2354.
15. Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD. A pooled analysis of exenatide use and risk of acute pancreatitis. Curr Med Res Opin 2013; 29(12): 1577-1586.
16. Chang HY, Clark JM, Weiner JP. Morbidity trajectories as predictors of utilization: multi-year disease patterns in Taiwan's national health insurance program. Med Care 2011; 49(10): 918-923.
17. Chang HY, Weiner JP. An in-depth assessment of a diagnosis-based risk adjustment model based on national health insurance claims: the application of the Johns Hopkins Adjusted Clinical Group case-mix system in Taiwan. BMC Med 2010; 8: 7.
18. Chang HY, Bodycombe DP, Huang WF, Weiner JP. Risk-adjusted resource allocation: using Taiwan's national health insurance as an example. Asia Pac J Public Health 2013. doi: 10.1177/1010539512471073.
19. Chang HY. The impact of morbidity trajectories on identifying high-cost cases: using Taiwan's national health insurance as an example. J Public Health (Oxf) 2013; 36(2): 300-307.
20. Yeh HT, Hsieh CF, Tsai YW, Huang WF. Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. Clin Ther 2012; 34(4): 885-893.
21. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308(18): 1906-1914.
22. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 2011; 33(9): 1173-1179.
23. Khardori R. Type 2 diabetes mellitus medication. 2014 2014/04/28 [cited 2014 2014/06/03]; Available from: http://emedicine.medscape.com/article/117853-medication
24. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Predicting costs with diabetes complications severity index in claims data. Am J Manag Care 2012; 18(4): 213-219.
25. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 2012; 18(11): 721-726.
26. Cowen ME, Dusseau DJ, Toth BG, Guisinger C, Zodet MW, Shyr Y. Casemix adjustment of managed care claims data using the clinical classification for health policy research method. Med Care 1998; 36(7): 1108-1113.
27. WHO Collaborating Centre for Drug Statistics Methodology. The ATC and DDD system. 2009, 2009-12-17 [cited 2014 06-03]; Available from: http://www.whocc.no/ddd/definition_and_general_considera/
28. Moores K, Gilchrist B, Carnahan R, Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 194-202.
29. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173(7): 534-539.
30. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46(3): 399-424.
31. Gonzalez-Perez A, Schlienger RG, Rodriguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010; 33(12): 2580-2585.
32. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012; 107(4): 620-626.
33. Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014; 2(2): 111-115.
34. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012; 61(5): 1250-1262.
35. Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106(1): 19-26.
36. Shen HN, Lu CL, Li CY. Epidemiology of first-attack acute pancreatitis in Taiwan from 2000 through 2009: a nationwide population-based study. Pancreas 2012; 41(5): 696-702.
37. Shen HN, Lu CL. Incidence, resource use, and outcome of acute pancreatitis with/without intensive care: a nationwide population-based study in Taiwan. Pancreas 2011; 40(1): 10-15.
38. Shen HN, Chang YH, Chen HF, Lu CL, Li CY. Increased risk of severe acute pancreatitis in patients with diabetes. Diabet Med 2012; 29(11): 1419-1424.
39. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011; 106(9): 1697-1704.
40. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35(2): 278-280.
41. Tseng CH. Body mass index and blood pressure in adult type 2 diabetic patients in Taiwan. Circ J 2007; 71(11): 1749-1754.
42. Nelson M, Bhandari N, Wener J. Sitagliptin-induced pancreatitis-a longer road than expected. Clin Case Rep 2014; 2(4): 149-152.